Robert James Wills - 20 Jun 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 20 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2024, 16:05:11 UTC
Prior SEC filing: 10 Apr 2024
Next SEC filing: 29 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/Chase C. Leavitt, Attorney-in-fact

Key filing fact

Robert James Wills filed Form 4 for Oncternal Therapeutics, Inc. on 24 Jun 2024.

Key facts

This page summarizes Robert James Wills's Form 4 filing for Oncternal Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jun 2024, 16:05.

Change

Previous filing in this sequence was filed on 10 Apr 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ONCT transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +2,200
Change %
Price: $0.000000
Shares after: 2,200
Date: 20 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,200
Exercise price: $8.10
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-twelfth of the number of shares subject to the option vest and become exercisable in substantially equal installments on each monthly anniversary of the grant date, subject to the Reporting Person's continued service through such vesting date.